Yahoo · Oct 9, 2026
Why Boston Scientific (BSX) Outpaced the Stock Market Today
Boston Scientific (BSX) reached $42.73 at the closing of the latest trading day, reflecting a +1.64% change compared to its last close.
NASDAQ · BSX
Boston Scientific Corporation
Healthcare · Medical - Devices
$43.31
Down-$0.76 (-1.74%)
Updated Oct 14, 2026, 5:34 PM
SID Score
5.1/10
Composite research score
Smart Money
63/100
Neutral
- Market cap
- 135.98B
- P/E ratio
- 48.75
- Dividend yield
- 0.00%
- 52-week range
- $41.39 – $100.90
- Volume
- 14.28M
- Avg. volume
- 9.87M
Price performance · BSX
BSX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
BSX closed at $43.31 after 21 trading sessions, down 1.28% for the selected period.
- Last close
- $43.31
- Period change
- -1.28%
- Period low
- $41.58
- Period high
- $44.92
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $43.95 | $44.1522 | $42.455 | $43.31 | 14.28M |
| Oct 12, 2026 | $43.10 | $43.92 | $42.67 | $43.84 | 13.6M |
| Oct 9, 2026 | $42.12 | $42.83 | $41.97 | $42.73 | 13.04M |
| Oct 8, 2026 | $41.50 | $42.27 | $41.385 | $42.04 | 22.88M |
| Oct 7, 2026 | $42.19 | $42.515 | $41.50 | $41.58 | 15.89M |
| Oct 6, 2026 | $42.47 | $42.75 | $41.995 | $42.19 | 12.55M |
| Oct 5, 2026 | $42.53 | $43.30 | $42.285 | $42.40 | 13.74M |
| Oct 2, 2026 | $43.315 | $43.44 | $41.9397 | $42.60 | 18.31M |
| Oct 1, 2026 | $43.51 | $43.96 | $42.95 | $43.23 | 17.94M |
| Sep 30, 2026 | $43.74 | $43.97 | $43.30 | $43.65 | 17.97M |
| Sep 29, 2026 | $44.145 | $44.30 | $43.22 | $43.88 | 14.61M |
| Sep 28, 2026 | $43.91 | $44.15 | $43.165 | $44.11 | 21.78M |
| Sep 25, 2026 | $44.68 | $44.84 | $43.325 | $43.92 | 15.21M |
| Sep 24, 2026 | $44.65 | $45.16 | $44.46 | $44.68 | 17.3M |
| Sep 23, 2026 | $45.00 | $45.74 | $43.985 | $44.62 | 18.57M |
| Sep 22, 2026 | $44.70 | $45.08 | $44.04 | $44.92 | 21.08M |
| Sep 21, 2026 | $42.98 | $43.81 | $42.72 | $43.72 | 25M |
| Sep 18, 2026 | $43.08 | $43.90 | $43.05 | $43.34 | 29.28M |
| Sep 17, 2026 | $43.465 | $43.66 | $42.95 | $43.55 | 32.57M |
| Sep 16, 2026 | $43.85 | $44.665 | $43.6501 | $43.91 | 28.48M |
| Sep 15, 2026 | $44.32 | $44.9889 | $43.68 | $43.87 | 16.02M |
Latest BSX news
The latest Smart Investors Daily articles mentioning BSX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BSX research
Overview
Company profile and research snapshot.
Company profile
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $127.00
- Implied upside
- —
- Analysts
- 24
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Oct 5, 2026 | Citigroup | Neutral | — |
| Sep 24, 2026 | Wells Fargo | Equal-Weight | — |
| Sep 21, 2026 | Oppenheimer | Outperform | — |
| Sep 17, 2026 | Citigroup | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 8, 2026
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Boston Scientific (BSX) concluded the recent trading session at $42.04, signifying a +1.11% move from its prior day's close.
Yahoo · Oct 8, 2026
Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Boston Scientific (BSX). This makes it worthwhile to examine what the stock has in store.
Yahoo · Oct 8, 2026
Why Is Boston Scientific (BSX) Reorganizing Into Three Segments Under A New COO?
Boston Scientific (NYSE: BSX) appointed Joseph M. Fitzgerald as executive vice president and chief operating officer, effective January 1, 2027. The company plans to reorganize its global operations into three reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg. Fitzgerald is expected to oversee the transition to the new segment structure as part of a broader operational realignment. The leadership change and shift to Interventional Therapies, Rhythm Solutions, and...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
